Overview
NICE is unable to make a recommendation on belimumab (Benlysta) for treating lupus nephritis. This is because GlaxoSmithKline did not provide an evidence submission.
Last reviewed: 13 July 2022
Next review: We will review this decision if the company decides to make a submission.